SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients.

Haeusler, Gabrielle M; Ammann, Roland A; Carlesse, Fabianne; Groll, Andreas H; Averbuch, Dina; Castagnola, Elio; Agyeman, Philipp K A; Phillips, Bob; Gilli, Flávio; Solopova, Galina; Attarbaschi, Andishe; Wegehaupt, Oliver; Speckmann, Carsten; Sung, Lillian; Lehrnbecher, Thomas (2021). SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients. European journal of cancer, 159, pp. 78-86. Elsevier 10.1016/j.ejca.2021.09.027

[img] Text
1-s2.0-S0959804921011278-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (515kB) | Request a copy

PURPOSE

There are limited data on SARS-CoV-2 (COVID-19) infection in children with cancer or after haematopoietic stem cell transplant (HSCT). We describe the severity and outcomes of SARS-COV-2 in these patients and identify factors associated with severe disease.

METHODS

This was a multinational, observational study of children (aged <19 years) with cancer or HSCT and SARS-CoV-2 confirmed by polymerase chain reaction. COVID-19 was classified as asymptomatic, mild, moderate, severe or critical (≥1 organ support). Exact polytomous regression was used to determine the relationship between clinical variables and disease severity.

RESULTS

One hundred and thirty-one patients with COVID-19 across 10 countries were identified (median age 8 years). Seventy-eight (60%) had leukaemia/lymphoma, 48 (37%) had solid tumour and five had primary immunodeficiency and HSCT. Fever (71%), cough (47%) and coryza (29%) were the most frequent symptoms. The median duration of detectable virus was 16 days (range, 1-79 days). Forty-nine patients (37%) were hospitalised for COVID-19 symptoms, and 15 (11%) required intensive care unit-level care. Chemotherapy was delayed/modified in 35% of patients. COVID-19 was asymptomatic in 32% of patients, mild in 47%, moderate in 8%, severe in 4% and critical in 9%. In 124 patients (95%), a full recovery was documented, and four (3%) died due to COVID-19. Any comorbidity (odds ratio, 2.94; 95% confidence interval [CI], 1.81-5.21), any coinfection (1.74; 95% CI 1.03-3.03) and severe baseline neutropenia (1.82; 95% CI 1.13-3.09) were independently and significantly associated with increasing disease severity.

CONCLUSION

Although most children with cancer had asymptomatic/mild disease, 13% had severe COVID-19 and 3% died. Comorbidity, coinfection and neutropenia may increase the risk of severe disease. Our data may help management decisions in this vulnerable population.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Paediatric Haematology/Oncology
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Paediatric Infectiology

UniBE Contributor:

Ammann, Roland and Agyeman, Philipp Kwame Abayie

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0959-8049

Publisher:

Elsevier

Language:

English

Submitter:

Anette van Dorland

Date Deposited:

04 Apr 2022 17:13

Last Modified:

28 Jul 2022 16:16

Publisher DOI:

10.1016/j.ejca.2021.09.027

PubMed ID:

34736044

Uncontrolled Keywords:

COVID-19 Cancer Chemotherapy Child Haematopoietic stem cell transplantation SARS-CoV-2

BORIS DOI:

10.48350/164411

URI:

https://boris.unibe.ch/id/eprint/164411

Actions (login required)

Edit item Edit item
Provide Feedback